Screening-first explainers for people comparing serious options — not psychedelic tourism content.
2026-09-06 · 10 min
PubMed stimulant pick: Schenberg Brazil ibogaine+psychotherapy abstinence (cocaine/crack-heavy)—oral≠IV; no cures; QTc; Schedule I.
Read article →2026-09-06 · 10 min
LABEL PRECLINICAL: Marton et al. 2019 Frontiers—ibogaine alters rat GDNF/BDNF; not human IV proof; no cures; QTc still relevant clinically.
Read article →2026-09-06 · 10 min
Human ibogaine PK: Glue 2015 CYP2D6 20 mg volunteer study—distinct from Glue noribogaine 88; bridge Knuijver 2024; oral≠IV; QTc.
Read article →2026-09-06 · 10 min
Davis et al. 2023 AJDAA prospective n=86 SOF open-label ibogaine+5-MeO—beyond MISTIC primary; oral≠IV; no cures; QTc; Schedule I.
Read article →2026-09-06 · 10 min
Ibogaine + IV magnesium QTc mitigation: Knuijver bolus methods + MISTIC context—beyond Cherian primary; oral≠IV psychoactive; Schedule I.
Read article →2026-09-06 · 10 min
Peer-reviewed methadone/agonist→ibogaine transition: Knuijver 2021 morphine conversion protocol—oral≠IV; QTc; Schedule I.
Read article →2026-09-06 · 10 min
No peer-reviewed Sisko paper found; substitute Davis 2018 mixed-method n=73 detox persisting effects—oral≠IV; QTc; Schedule I.
Read article →2026-09-06 · 10 min
Davis & Barsuglia 2017 J Psychedelic Studies: n=88 Mexico ibogaine survey—oral≠IV; no cures; QTc; Schedule I.
Read article →2026-09-06 · 10 min
Malcolm et al. 2018 J Psychoactive Drugs: n=50 OUD COWS/SOWS/BSCS observational detox—oral≠IV; no cures; QTc; Schedule I.
Read article →2026-09-06 · 11 min
LABEL PRECLINICAL: O’Hearn/Molliver Purkinje degeneration + dose-response; link Knuijver human ataxia—not IV proof; QTc; Schedule I.
Read article →2026-09-06 · 10 min
Mash 2023 Pharmacol Res IUPHAR review: ibogaine/NIDA-FDA pathway historical perspective—oral≠IV; no cures; QTc; Schedule I; COI noted.
Read article →2026-09-06 · 10 min
LABEL PRECLINICAL: 18-MC (18-methoxycoronaridine) Glick-line rodent antiaddiction vs ibogaine toxicity—not human IV proof; QTc; Schedule I.
Read article →2026-09-06 · 10 min
Olash et al. 2026 npj Ment Health Res: MISTIC veteran narrative themes—oral ibogaine + IV Mg, not psychoactive IV proof; QTc; Schedule I.
Read article →2026-09-06 · 10 min
Corkery JM 2018 Prog Brain Res: ibogaine fatality update (33 deaths, 5 UK)—risk-benefit chapter; oral≠IV; QTc; Schedule I.
Read article →2026-09-06 · 11 min
Heink et al. 2017 J Psychoactive Drugs: retrospective 5D-ASC survey of ibogaine use contexts—oral≠IV; not RCT; QTc; Schedule I.
Read article →2026-09-06 · 10 min
Brown, Noller & Denenberg 2019 J Psychoactive Drugs: SCQ + qualitative follow-on to Brown/Alper & Noller OUD cohorts—oral≠IV; no cures; QTc.
Read article →2026-09-06 · 10 min
LABEL PRECLINICAL: Cameron et al. Nature 2020/21 tabernanthalog—rodent plasticity/addiction models; not approved; ≠IV ibogaine; cardiac-risk contrast careful.
Read article →2026-09-06 · 10 min
LABEL PRECLINICAL: Alper 2016 Cardiovasc Toxicol + Koenig hERG work—ibogaine/noribogaine block IKr. Mechanistic≠human efficacy; oral≠IV; QTc risk.
Read article →2026-09-06 · 10 min
Sharma et al. J Psychopharmacol 2026: only 3 RCTs; sequential/microdosing experimental; cardiotoxicity—clinical use not recommended pending larger trials.
Read article →2026-09-06 · 10 min
Esperança et al. Molecules 2026 scoping review: ibogaine SUD potential vs cardiac safety, hERG/QTc, fragmented evidence. Review≠cure; oral≠IV.
Read article →2026-09-06 · 10 min
Schep et al. Drug Alcohol Depend 2016: ibogaine toxicity, arrhythmias, deaths; calculated ~0.87 mg/kg starting-dose caution. Review≠cure; oral≠IV.
Read article →2026-09-06 · 11 min
Litjens & Brunt Clin Toxicol 2016 review: ibogaine PK, hERG cardiotoxicity, cerebellar neurotoxicity themes. Review ≠ cure; oral≠IV; Schedule I.
Read article →2026-09-06 · 11 min
Glue et al. J Clin Pharmacol 2015: oral noribogaine 3–60 mg in 36 healthy men—PK/safety Phase 1. Oral noribogaine ≠ IV ibogaine; later QTc signals matter.
Read article →2026-09-06 · 11 min
Brody & Siddiqi Nat Med 2024 commentary on Cherian MISTIC: oral ibogaine + IV Mg, not psychoactive IV proof; calls for controlled cardiac-safety trials.
Read article →2026-09-06 · 11 min
Świeczkowski et al. J Psychoactive Drugs 2025: cross-section of 9 early ibogaine trials—landscape ≠ personal access; cardiac safety; not IV proof.
Read article →2026-09-06 · 12 min
Davis et al. Chronic Stress 2020: retrospective survey of oral ibogaine then 5-MeO-DMT in SOF veterans—not psychoactive IV proof; confounders matter.
Read article →2026-09-06 · 9 min
Brunt Addiction review: rare but relevant ibogaine QTc prolongation & ventricular arrhythmias/TdP; CYP2D6; medical supervision—not IV proof.
Read article →2026-09-06 · 9 min
Rocha et al. Eur Arch Psychiatry Clin Neurosci 2023: setting factors for safer ibogaine—medical monitoring essential; not IV efficacy proof.
Read article →2026-09-06 · 9 min
Ona et al. Psychopharmacology 2022: AE systematic review 2015–2020—18 studies; acute QTc/GI/neuro AEs; need Phase I & screening—not IV proof.
Read article →2026-09-06 · 10 min
Belgers 2016 Transl Psychiatry: PRECLINICAL animal meta-analysis—reduced self-administration signals + motor/cerebellar toxicity; NOT human efficacy proof.
Read article →2026-09-06 · 9 min
Kervadec et al. J Clin Psychopharmacol 2026: 30-year narrative review—insufficient evidence for clinical use; no DB RCT for OUD; cardiotoxicity risk.
Read article →2026-09-06 · 11 min
Knuijver 2024 J Psychopharmacol: oral ibogaine 10 mg/kg n=14; CYP2D6 clearance drives exposure; QTc tied to ibogaine conc—not IV proof.
Read article →2026-09-06 · 10 min
Mosca et al. Curr Neuropharmacol 2023 systematic review: SUD efficacy signals vs cardiotoxicity/mortality; limited RCTs—not IV-ibogaine proof; screening first.
Read article →2026-09-06 · 10 min
Köck et al. JSAT 2022 systematic review: 24 studies / 705 people—withdrawal/craving signals plus deaths/complications; need medical settings; not IV-ibogaine proof.
Read article →2026-09-06 · 11 min
Knuijver et al. Addiction 2021: oral ibogaine 10 mg/kg n=14; mean QTc +95 ms; 50% >500 ms; severe ataxia; no TdP in sample—serious cardiac teaching, not IV proof.
Read article →2026-09-06 · 11 min
Glue et al. 2016 Clin Pharmacol Drug Dev: DBPC oral noribogaine in opioid-dependent patients; QTcI rose ~16–42 ms by dose. Noribogaine ≠ IV ibogaine brand.
Read article →2026-09-06 · 12 min
Mash et al. 2018 Front Pharmacol open-label N=191 oral ibogaine: opioid/cocaine craving & withdrawal signals—not RCT; not IV-ibogaine proof. QTc risk remains.
Read article →2026-09-06 · 14 min
Noller et al. 2018 Am J Drug Alcohol Abuse n=14 NZ oral ibogaine: 12-mo ASI/BDI gains; ONE death during treatment—discuss honestly. Not IV-ibogaine proof.
Read article →2026-09-06 · 11 min
Brown & Alper 2018 observational n=30 OUD: oral ibogaine HCl ~1540 mg, SOWS drop, 50% no opioids prior 30 days at 1 month—not RCT; cardiac risk; not IV proof.
Read article →2026-09-06 · 12 min
Translational Psychiatry 2026 MISTIC 12-month follow-up (n=25/30): durable oral ibogaine + IV Mg signals—not IV-ibogaine proof. Confounders; RCTs needed.
Read article →2026-09-06 · 9 min
Ibogaine telemetry and ACLS monitoring: why continuous ECG, emergency readiness, and QTc screening are floors for IV psychoactive ibogaine—not spa upgrades.
Read article →2026-09-06 · 9 min
Ibogaine questions to ask a clinic before consent: route, QTc monitoring, oral vs IV honesty, MISTIC myths, Mexico provisional. No cure claims.
Read article →2026-09-06 · 10 min
Ibogaine vs psilocybin therapy: legality, QTc risk, session design, evidence maturity. IV ibogaine infusion ≠ psilocybin. Oral-evidence gap; no cures; Mexico provisional.
Read article →2026-09-06 · 10 min
Ibogaine and pre-existing heart conditions: QTc, long QT, arrhythmia history, screening exclusions. IV psychoactive entity; oral-evidence gap; no DIY; Mexico provisional.
Read article →2026-09-06 · 9 min
Ibogaine and liver health: hepatic screening themes, metabolism considerations, QTc still first. IV psychoactive entity; oral-evidence gap; no DIY; Mexico provisional.
Read article →2026-09-06 · 9 min
Ibogaine vs 5-MeO-DMT: chemistry, duration, cardiac QTc vs other risks, oral vs IV honesty. No cure claims. Not FDA-approved. Screening-first.
Read article →2026-09-06 · 9 min
Ibogaine CYP2D6 metabolism: noribogaine conversion, poor metabolizers, inhibitor interactions, QTc exposure link. Oral PK evidence; IV honesty. No DIY.
Read article →2026-09-06 · 11 min
Ibogaine success stories are anecdotes—not evidence. How to read testimonials without cure claims. Oral vs IV gap; QTc risk; red-flag marketing; Mexico provisional.
Read article →2026-09-06 · 9 min
Searching ibogaine clinic near me? Ibogaine is Schedule I / not FDA-approved in the US. Programs discussed here are provisionally in Mexico—not a US storefront. QTc first.
Read article →2026-09-06 · 10 min
Ibogaine withdrawal vs medical detox: IV ibogaine infusion is not an FDA detox substitute. QTc risk, oral-evidence gap, MOUD contrast, Mexico provisional. No cures.
Read article →2026-09-06 · 10 min
Ibogaine vs kratom: not interchangeable. IV ibogaine infusion is physician-supervised psychoactive IV with QTc risk; kratom is a different plant product. No cures; Schedule I.
Read article →2026-09-06 · 11 min
Ibogaine for TBI veterans: Cherian/MISTIC Nature Medicine 2024 was oral ibogaine + IV magnesium—open-label, not IV-ibogaine proof or a TBI cure. QTc first; Schedule I.
Read article →2026-09-06 · 10 min
Ibogaine integration therapy explained: after IV ibogaine infusion, therapy supports meaning and relapse planning—not a guaranteed cure. QTc follow-up, oral-lit gap.
Read article →2026-09-06 · 10 min
Ibogaine for nicotine or smoking: limited controlled evidence, oral-lit gap vs IV ibogaine infusion, QTc risk, Schedule I, Mexico provisional, no cure claims.
Read article →2026-09-06 · 10 min
Ibogaine FDA IND explained: an IND enables investigational research—not approval. Legacy IND history, oral-lit gap, QTc risk, Schedule I, vs IV ibogaine infusion.
Read article →2026-09-06 · 10 min
Magnesium ibogaine cardiac protocol explained: IV magnesium is support for QTc risk mitigation—not psychoactive IV ibogaine. Oral-lit gap, Schedule I, no DIY.
Read article →2026-09-06 · 10 min
Ibogaine test dose and flood dose explained as oral-literature protocol labels—not DIY instructions—and how they differ from physician-supervised IV ibogaine infusion.
Read article →2026-09-06 · 10 min
How to read an ibogaine clinic website: decode oral vs IV, support Mg vs psychoactive IV, QTc honesty, cure claims, Schedule I, Mexico provisional vs tourism.
Read article →2026-09-06 · 9 min
Ibogaine vs naltrexone for addiction: antagonist maintenance vs experimental psychoactive IV infusion. QTc risk, legality, no cure claims, screening first.
Read article →2026-09-06 · 9 min
Ibogaine luxury retreat red flags: infinity pools ≠ ACLS. Demand QTc screening, telemetry, route honesty. IV psychoactive ≠ Mg drip. No cure claims.
Read article →2026-09-06 · 9 min
Preparing for ibogaine screening: ECG, electrolytes, medication list, history. IV psychoactive ibogaine QTc focus. No DIY; no cure claims. Soft CTA to apply.
Read article →2026-09-06 · 9 min
Ibogaine and SSRIs / psychiatric meds: educational interaction and taper cautions only—not a DIY plan. QTc risk, screening, physician-directed decisions.
Read article →2026-09-06 · 9 min
Ibogaine mortality and cardiac risk: QTc prolongation, arrhythmia concerns, screening, monitoring. IV psychoactive ibogaine ≠ oral lit. No DIY; no cure claims.
Read article →2026-09-06 · 10 min
Family guide to ibogaine treatment: what IV ibogaine infusion is, QTc risk, screening questions, red flags, aftercare—and why there are no cure guarantees.
Read article →2026-09-06 · 10 min
Ibogaine vs MDMA-assisted therapy: different drugs, evidence paths, cardiac risk, and legality. IV ibogaine infusion ≠ MDMA PTSD protocols. No cure claims.
Read article →2026-09-06 · 9 min
Ibogaine drug interactions and QTc risk: QT-prolonging meds, CYP2D6 inhibitors, electrolytes, oral vs IV honesty. No DIY. Not FDA-approved.
Read article →2026-09-06 · 9 min
Ibogaine and benzodiazepines: educational taper/warning themes, seizure risk, physician-owned decisions, QTc screening. No DIY. Not FDA-approved.
Read article →2026-09-06 · 10 min
What to expect from IV ibogaine treatment: screening, cardiac monitoring, session flow, integration. Oral vs IV honesty; no cure claims. Not FDA-approved.
Read article →2026-09-06 · 10 min
Flying home after IV ibogaine infusion: cardiac caution, oral-lit gap, Mexico provisional reality, no DIY boosters, aftercare before the airport finish line.
Read article →2026-09-06 · 11 min
Ibogaine for anxiety: limited controlled evidence, oral-literature gap vs IV ibogaine infusion, QTc risk first, no cure claims, Schedule I / Mexico provisional.
Read article →2026-09-06 · 8 min
Ibogaine microdosing myths debunked: no safe DIY schedule, QTc risk still applies, oral vs IV honesty. Not FDA-approved. Screening-first medical model.
Read article →2026-09-06 · 10 min
Ibogaine for cocaine and stimulants: thin human evidence, oral vs IV honesty, QTc/cardiac risk, no cure claims. Not FDA-approved. Screening-first.
Read article →2026-09-06 · 10 min
Ibogaine aftercare and integration after IV ibogaine infusion: relapse risk honesty, no cure claims, cardiac follow-up questions, screening-first CTA.
Read article →2026-09-06 · 10 min
State ibogaine research bills 2026 landscape: funding and proposed trials ≠ walk-in access or FDA approval. Texas SB 2308 context; QTc; oral vs IV honesty.
Read article →2026-09-06 · 11 min
Ibogaine for alcohol use disorder: thin evidence, noribogaine trial interest, oral vs IV honesty, QTc risk. No cure claims. Not FDA-approved.
Read article →2026-09-06 · 10 min
Noribogaine clinical trial headlines vs IV ibogaine infusion: metabolite / oral investigational products are not the same as psychoactive IV ibogaine. QTc; no cures.
Read article →2026-09-06 · 10 min
Ibogaine Mexico treatment: provisional medical IV programs vs ceremony/tourism. Screening, telemetry, oral vs IV honesty. Not FDA/US clinic; not legal advice.
Read article →2026-09-06 · 11 min
Ibogaine success rate / cure rate claims debunked: why viral “80% cured” stats fail. Small open-label ≠ cure rate. QTc risk; red-flag clinics; no guarantees.
Read article →2026-09-06 · 10 min
Ibogaine Right to Try for veterans as reported in 2026: EO framing does not erase Schedule I or create FDA approval. QTc risk, Mexico provisional vs US research.
Read article →2026-09-06 · 13 min
Texas ibogaine clinical trials explained: SB 2308 / UTHealth Houston + UTMB $50M research landscape as reported in 2026. Trials ≠ walk-in access; QTc still matters.
Read article →2026-09-06 · 9 min
Noribogaine explained: ibogaine’s active metabolite, why it appears in craving/mood discussions, oral-evidence gap, QTc context, and how it relates to IV ibogaine infusion.
Read article →2026-09-03 · 9 min
Ibogaine treatment duration explained: how long a physician-supervised IV ibogaine infusion program lasts, monitoring windows, oral-evidence gap, and aftercare—not a cure timeline.
Read article →2026-08-31 · 9 min
Ibogaine treatment resistant depression: investigational interest vs ketamine evidence maturity, oral-literature gap, QTc risk, and why there are no cure claims.
Read article →2026-08-24 · 9 min
Does insurance cover ibogaine? Usually not for Schedule I / non-FDA-approved care. Learn cash-pay realities, IV infusion context, and what to ask before deposits.
Read article →2026-08-17 · 9 min
Ibogaine electrolyte protocol explained: support IV (magnesium/fluids) vs psychoactive IV ibogaine infusion, QTc risk, and why oral research must not be blurred as IV proof.
Read article →2026-08-10 · 10 min
Ibogaine contraindications and who should not receive IV ibogaine: cardiac QTc risk, screening exclusions, oral-evidence gap, and why medical clearance is non-negotiable.
Read article →2026-08-03 · 10 min
Ibogaine vs Suboxone (buprenorphine) compared: MOUD evidence vs investigational IV ibogaine infusion, precipitated-withdrawal caution, QTc risk, oral-evidence gap.
Read article →2026-07-27 · 10 min
Ibogaine vs methadone compared honestly: MOUD evidence vs investigational IV ibogaine infusion, QTc risk, oral-literature gap, Schedule I status—no cure claims.
Read article →2026-07-20 · 12 min
Ibogaine for fentanyl: observational oral-literature interest, cardiac QTc risk, IV psychoactive infusion context, and why there is no proven cure or FDA approval.
Read article →2026-07-13 · 10 min
Ibogaine side effects include QTc prolongation/arrhythmia risk, nausea, ataxia, and prolonged intensity. IV infusion still needs monitoring; literature is mostly oral.
Read article →2026-07-06 · 9 min
Cheap ibogaine clinic risks: red flags include route opacity (oral vs IV), missing ECG/telemetry, cure guarantees, and citing oral studies as IV proof.
Read article →2026-06-29 · 9 min
Stanford-affiliated MISTIC / Cherian Nature Medicine 2024 used oral ibogaine + IV magnesium in veterans (open-label n≈30)—not IV-ibogaine proof. RCTs needed.
Read article →2026-06-22 · 10 min
Ibogaine treatment package inclusions for IV ibogaine infusion: screening, telemetry, physician oversight, support IV labeled separately, integration—and red flags.
Read article →2026-06-15 · 10 min
Ibogaine vs traditional rehab: compare setting, duration, evidence maturity, and cardiac risk. IV ibogaine infusion is not a rehab substitute or cure.
Read article →2026-06-08 · 10 min
Ibogaine ECG requirements and pre-infusion checklist: QTc review, electrolytes, meds, continuous telemetry for IV ibogaine infusion—plus oral-literature context.
Read article →2026-06-01 · 11 min
Is ibogaine legal in the US? It is Schedule I federally and not FDA-approved. Learn what that means for IV ibogaine infusion education—not legal advice.
Read article →2026-05-25 · 12 min
Ibogaine oral vs IV explained: most published studies use oral HCl (± IV magnesium support). Learn how that differs from psychoactive IV ibogaine infusion.
Read article →2026-05-18 · 12 min
Ibogaine vs ayahuasca: IV psychoactive ibogaine under MD supervision vs ceremony—chemistry, QTc vs MAOI risks, oral-evidence gap, settings.
Read article →2026-05-05 · 15 min
How to choose an ibogaine clinic: 14-point checklist for IV vs oral clarity, ECG/telemetry, MD oversight, cost transparency, and red flags.
Read article →2026-04-22 · 10 min
IV ibogaine infusion cost typically ranges ~$6k–$25k by medical tier. See what physician supervision, monitoring, and infusion care should include—and red flags.
Read article →2026-04-10 · 11 min
Ibogaine can prolong QTc and raise arrhythmia risk. Learn cardiac screening, ECG, electrolytes, continuous monitoring for IV ibogaine infusion, and oral-lit context.
Read article →2026-03-28 · 10 min
IV ibogaine infusion vs ketamine infusion: legality, evidence maturity, session design, cardiac risk—and why they share an IV journey model but are not interchangeable.
Read article →2026-03-12 · 15 min
IV ibogaine infusion is intravenous psychoactive ibogaine under physician supervision—with cardiac monitoring. Learn definition, oral-evidence gap, legality, and safety.
Read article →